BACKGROUND: Fluorouracil (5-FU), oxaliplatin and irinotecan combinations improve 
time to tumor progression (TTP), objective response and overall survival (OS) in 
patients with metastatic colorectal cancer (MCRC). Here we identify and describe 
patients treated on Intergroup study N9741 who initially had inoperable MCRC, 
but who obtained sufficient chemotherapeutic benefit to allow removal of their 
metastatic disease.
PATIENTS AND METHODS: Patient research records in study arms (A) 
irinotecan/5-FU/leucovorin (LV) (IFL, n = 264), (F) oxaliplatin/5-FU/LV 
(FOLFOX4, n = 267) and (G) oxaliplatin/irinotecan (IROX, n = 265) were reviewed. 
TTP and median OS were calculated.
RESULTS: Twenty-four (3.3%) of 795 randomized patients underwent curative 
metastatic disease resection [hepatectomy, 16; radiofrequency-ablation (RFA), 
six; lung resection, two]. Twenty-two out of 24 (92%) resected patients received 
an oxaliplatin-based regimen (FOLFOX4, 11; IROX, 11). Seven patients (29.2%) 
remain disease-free; relapses occurred mainly in the resected organ. Median OS 
in resected patients is 42.4 months, and median TTP is 18.4 months. All six 
patients treated with RFA have recurred. Four out of five (80%) patients who 
received chemotherapy following resection are disease-free.
CONCLUSIONS: Resection of metastatic disease after chemotherapy is possible in a 
small but important subset of patients with MCRC, particularly after receiving 
an oxaliplatin-based chemotherapy regimen, with encouraging OS and TTP observed 
in these highly selected patients.